Thiogenesis reports 2026 annual and special meeting results
Thiogenesis Therapeutics announced results of its 2026 annual and special meeting of shareholders and provided a corporate update.
Story updates
08:01:54 AM UTC
SquawkNews
Thiogenesis Therapeutics, Corp. said shareholders approved all AGM items and it plans to start an investigator-initiated cystinosis study and a Phase 2a Leigh syndrome trial of TTI-0102 in Q4 2026, with topline data expected in H1 2027.Material DetailsContext by AI AnalystThis is an early-stage cli…
Thiogenesis Therapeutics, Corp. said shareholders approved all items at its annual and special meeting. The company said it plans to begin an investigator-initiated cystinosis study and a Phase 2a Leigh syndrome trial of TTI-0102 in Q4 2026, with topline data expected in H1 2027.